The related data indicate that LAT1/4F2hc is highly expressed in human gliomas, and associated with glioma progression as well as the poor prognosis of glioma patients [17]; furthermore, treatment of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), a system L selective inhibitor, exerts significant cytotoxic effects, with reduced proliferation and increased apoptosis rates in glioma cells with high LAT1 expression [18]. The gene discussed is SLC3A2; the disease is central nervous system cancer.